Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0722
Source ID: NCT00472082
Associated Drug: Efalizumab
Title: Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
Acronym:
Status: TERMINATED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00472082/results
Conditions: Kidney Transplantation|Chronic Kidney Failure
Interventions: DRUG: efalizumab
Outcome Measures: Primary: Efficacy Will be Determined by Change in Renal Function as Measured by Cold Iothalamate Glomerular Filtration Rate(GFR)3 Months After Enrollment, and Acute Rejection Episodes Within the First 6 Months Post Enrollment., 6 months from conversion | Secondary: Safety, Including Incidence of Post- Transplant Infections, Malignancies, Morbidities, Hypertension, Glucose Intolerance, Serum Cholesterol and Triglycerides Profile Over Time, Development of New Anti-donor Antibodies., 1 year
Sponsor/Collaborators: Sponsor: Emory University | Collaborators: Genentech, Inc.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1|PHASE2
Enrollment: 5
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2007-05
Completion Date: 2009-04
Results First Posted: 2012-12-06
Last Update Posted: 2014-01-27
Locations: Emory University, Atlanta, Georgia, 30322, United States
URL: https://clinicaltrials.gov/show/NCT00472082